Form 4: Verona Pharma Chief Medical Officer Sells 240,000 Ordinary Shares

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma, sold 240,000 ordinary shares at an average price of $4.9015 per share.

Summary

• Kathleen A. Rickard, the Chief Medical Officer of Verona Pharma, sold 240,000 ordinary shares on November 25, 2024.
• The shares were sold at a weighted average price of $4.9015 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 17, 2023.
• The total number of ordinary shares beneficially owned by Ms. Rickard after the transaction is 2,671,480.
• The shares are represented by American Depositary Shares (ADSs), with each ADS representing eight ordinary shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It does not suggest any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice for executives at publicly traded companies to avoid accusations of insider trading.
• The sale of shares by a Chief Medical Officer is not unusual and is often part of personal financial planning.
• The volume of shares sold is not significant compared to the total outstanding shares of the company.

Stakeholder Impact

• The sale of shares by a company officer may have a minor impact on investor sentiment, but is unlikely to significantly affect the share price due to the pre-arranged nature of the sale.

Key Dates

Keywords

Verona Pharma, Kathleen A. Rickard, Chief Medical Officer, share sale, Rule 10b5-1, insider trading, VRNA, ordinary shares, ADS